vs

Side-by-side financial comparison of KORU Medical Systems, Inc. (KRMD) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.

TRANSACT TECHNOLOGIES INC is the larger business by last-quarter revenue ($11.5M vs $10.9M, roughly 1.1× KORU Medical Systems, Inc.). On growth, KORU Medical Systems, Inc. posted the faster year-over-year revenue change (23.3% vs 11.9%). KORU Medical Systems, Inc. produced more free cash flow last quarter ($687.0K vs $589.0K). Over the past eight quarters, KORU Medical Systems, Inc.'s revenue compounded faster (15.3% CAGR vs 3.5%).

KORU Medical Systems, Inc. is a specialized medical technology company that designs, manufactures, and distributes innovative ambulatory infusion systems and supporting disposable products. It caters to healthcare providers and patients across home care, clinical trial, and acute care segments worldwide, with a focus on enhancing the safety and comfort of specialty medication delivery.

Roper Technologies, Inc. is a holding company that owns companies in the technology sector.

KRMD vs TACT — Head-to-Head

Bigger by revenue
TACT
TACT
1.1× larger
TACT
$11.5M
$10.9M
KRMD
Growing faster (revenue YoY)
KRMD
KRMD
+11.3% gap
KRMD
23.3%
11.9%
TACT
More free cash flow
KRMD
KRMD
$98.0K more FCF
KRMD
$687.0K
$589.0K
TACT
Faster 2-yr revenue CAGR
KRMD
KRMD
Annualised
KRMD
15.3%
3.5%
TACT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
KRMD
KRMD
TACT
TACT
Revenue
$10.9M
$11.5M
Net Profit
Gross Margin
62.6%
47.6%
Operating Margin
-5.0%
-10.1%
Net Margin
Revenue YoY
23.3%
11.9%
Net Profit YoY
EPS (diluted)
$-0.11
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KRMD
KRMD
TACT
TACT
Q4 25
$10.9M
$11.5M
Q3 25
$10.4M
$13.2M
Q2 25
$10.2M
$13.8M
Q1 25
$9.6M
$13.1M
Q4 24
$8.8M
$10.2M
Q3 24
$8.2M
$10.9M
Q2 24
$8.4M
$11.6M
Q1 24
$8.2M
$10.7M
Net Profit
KRMD
KRMD
TACT
TACT
Q4 25
Q3 25
$-778.0K
$15.0K
Q2 25
$-206.9K
$-143.0K
Q1 25
$-1.2M
$19.0K
Q4 24
Q3 24
$-1.6M
$-551.0K
Q2 24
$-988.7K
$-319.0K
Q1 24
$-1.9M
$-1.0M
Gross Margin
KRMD
KRMD
TACT
TACT
Q4 25
62.6%
47.6%
Q3 25
60.2%
49.8%
Q2 25
63.5%
48.2%
Q1 25
62.8%
48.7%
Q4 24
62.9%
44.2%
Q3 24
63.4%
48.1%
Q2 24
65.0%
52.7%
Q1 24
62.3%
52.6%
Operating Margin
KRMD
KRMD
TACT
TACT
Q4 25
-5.0%
-10.1%
Q3 25
-8.3%
0.1%
Q2 25
-3.1%
-1.9%
Q1 25
-12.9%
-0.1%
Q4 24
-18.0%
-10.3%
Q3 24
-20.8%
-7.7%
Q2 24
-14.1%
-3.8%
Q1 24
-23.9%
-12.2%
Net Margin
KRMD
KRMD
TACT
TACT
Q4 25
Q3 25
-7.5%
0.1%
Q2 25
-2.0%
-1.0%
Q1 25
-12.1%
0.1%
Q4 24
Q3 24
-19.3%
-5.1%
Q2 24
-11.7%
-2.8%
Q1 24
-23.6%
-9.7%
EPS (diluted)
KRMD
KRMD
TACT
TACT
Q4 25
$-0.11
$-0.11
Q3 25
$0.02
$0.00
Q2 25
$0.00
$-0.01
Q1 25
$0.03
$0.00
Q4 24
$-0.22
$-0.80
Q3 24
$0.03
$-0.06
Q2 24
$0.02
$-0.03
Q1 24
$0.04
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KRMD
KRMD
TACT
TACT
Cash + ST InvestmentsLiquidity on hand
$8.9M
$20.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$17.0M
$31.1M
Total Assets
$28.2M
$44.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KRMD
KRMD
TACT
TACT
Q4 25
$8.9M
$20.4M
Q3 25
$8.5M
$20.0M
Q2 25
$8.1M
$17.7M
Q1 25
$8.7M
$14.2M
Q4 24
$9.6M
$14.4M
Q3 24
$8.8M
$11.3M
Q2 24
$10.5M
$11.1M
Q1 24
$10.8M
$10.6M
Stockholders' Equity
KRMD
KRMD
TACT
TACT
Q4 25
$17.0M
$31.1M
Q3 25
$16.5M
$31.8M
Q2 25
$16.5M
$31.3M
Q1 25
$16.3M
$30.9M
Q4 24
$16.8M
$30.6M
Q3 24
$17.7M
$38.4M
Q2 24
$18.7M
$38.5M
Q1 24
$19.1M
$38.6M
Total Assets
KRMD
KRMD
TACT
TACT
Q4 25
$28.2M
$44.8M
Q3 25
$27.1M
$45.0M
Q2 25
$25.5M
$44.5M
Q1 25
$27.2M
$44.2M
Q4 24
$27.2M
$44.0M
Q3 24
$27.4M
$50.5M
Q2 24
$27.3M
$50.4M
Q1 24
$27.5M
$51.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KRMD
KRMD
TACT
TACT
Operating Cash FlowLast quarter
$1.1M
$609.0K
Free Cash FlowOCF − Capex
$687.0K
$589.0K
FCF MarginFCF / Revenue
6.3%
5.1%
Capex IntensityCapex / Revenue
3.7%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-470.1K
$7.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KRMD
KRMD
TACT
TACT
Q4 25
$1.1M
$609.0K
Q3 25
$65.5K
$3.6M
Q2 25
$-460.3K
$3.6M
Q1 25
$-237.5K
$-161.0K
Q4 24
$939.6K
$2.4M
Q3 24
$-923.9K
$327.0K
Q2 24
$11.3K
$636.0K
Q1 24
$-346.7K
$-1.5M
Free Cash Flow
KRMD
KRMD
TACT
TACT
Q4 25
$687.0K
$589.0K
Q3 25
$13.0K
$3.6M
Q2 25
$-489.2K
$3.6M
Q1 25
$-680.9K
$-171.0K
Q4 24
$896.0K
$2.4M
Q3 24
$-2.0M
$259.0K
Q2 24
$-112.9K
$499.0K
Q1 24
$-479.8K
$-1.6M
FCF Margin
KRMD
KRMD
TACT
TACT
Q4 25
6.3%
5.1%
Q3 25
0.1%
27.1%
Q2 25
-4.8%
25.9%
Q1 25
-7.1%
-1.3%
Q4 24
10.1%
23.2%
Q3 24
-24.5%
2.4%
Q2 24
-1.3%
4.3%
Q1 24
-5.9%
-14.9%
Capex Intensity
KRMD
KRMD
TACT
TACT
Q4 25
3.7%
0.2%
Q3 25
0.5%
0.5%
Q2 25
0.3%
0.1%
Q1 25
4.6%
0.1%
Q4 24
0.5%
0.1%
Q3 24
13.2%
0.6%
Q2 24
1.5%
1.2%
Q1 24
1.6%
1.0%
Cash Conversion
KRMD
KRMD
TACT
TACT
Q4 25
Q3 25
242.00×
Q2 25
Q1 25
-8.47×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KRMD
KRMD

US$8.3M76%
Non Us$2.6M24%

TACT
TACT

Segment breakdown not available.

Related Comparisons